We can't find the internet
Attempting to reconnect
15808.1 PFLS-LS
15808.1 PFLS-LS
Zusammenfassung
Development of a novel somatostatin analogue G02113 for the treatment of acromegaly and neuroendocrine tumours
Weitere Texte
Abstract
The aim of this project is to complete key early developmental experiments for an anti-tumour peptide analogue therapy for patients with rare neuroendocrine tumours or acromegaly resistant, or poorly controlled, with available somatostatin analogues. The peptide analogue has high affinity for the two most important somatostatin receptors in growth hormone control, SSTR2 and 5. This novel tandem therapy will provide enhanced life expectancy, better clinical control and improved quality-of-life to the population of uncontrolled patients.
Beteiligte
Alan Harris
Wirtschaftspartner
Alan.harris@sompharmaceuticals.com
Sompharmaceuticals S.A. Alan Harris 1066 Epalinges VD CH
Eric Grouzmann
Kontaktperson
eric.grouzmann@chuv.ch
CHUV Centre Hospitalier Universitaire Va Division de pharmacologie et toxicologie cliniques Eric Grouzmann Av. de Beaumont 29 1011 Lausanne VD CH
Projektdetails
- Forschungsstelle
- INNOSUISSE
- Projektstatus
- Abgeschlossen
- Projekttyp
- Forschungsprojekt
- Startdatum
- 2013-10-31
- Enddatum
- 2015-07-31
- Bewilligte Gesamtkosten
- CHF 270040.00
- Sektion
- 20 Förderbereich Life Sciences
- NABS Politikbereich
- Industrielle Produktivität und Technologie
Forschungsdisziplinen
- T490 Biotechnology 100.0%